Biological Trace Element Research

, Volume 133, Issue 2, pp 136–143 | Cite as

Short-Term Oral Magnesium Supplementation Suppresses Bone Turnover in Postmenopausal Osteoporotic Women

  • Hasan AydınEmail author
  • Oğuzhan Deyneli
  • Dilek Yavuz
  • Hülya Gözü
  • Nilgün Mutlu
  • Işık Kaygusuz
  • Sema Akalın


Magnesium has been shown to increase bone mineral density when used in the treatment of osteoporosis, yet its mechanism of action is obscure. In this study, the effects of daily oral magnesium supplementation on biochemical markers of bone turnover were investigated. Twenty postmenopausal women have been divided into two groups. Ten patients were given magnesium citrate (1,830 mg/day) orally for 30 days. Ten postmenopausal women of matching age, menopause duration, and BMI were recruited as the control group and followed without any medication. Fasting blood and first-void urine samples were collected on days 0, 1, 5, 10, 20, and 30, respectively. Total magnesium, calcium, phosphorus, iPTH and osteocalcin were determined in blood samples. Deoxypyridinoline levels adjusted for creatinine were measured in urine samples. Thirty consecutive days of oral magnesium supplementation caused significantly decrease in serum iPTH levels in the Mg-supplemented group (p < 0.05). Serum osteocalcin levels were significantly increased (p < 0.001) and urinary deoxypyridinoline levels were decreased (p < 0.001) in the Mg-supplemented group. This study has demonstrated that oral magnesium supplementation in postmenopausal osteoporotic women suppresses bone turnover.


Postmenopausal osteoporosis Magnesium Bone turnover 


  1. 1.
    Tranquilli AL, Lucino E, Garzetti GG, Romanini C (1994) Calcium, phosphorus and magnesium intakes correlate with bone mineral content in postmenopausal women. Gynecol Endocrinol 1:55–58CrossRefGoogle Scholar
  2. 2.
    Reginster JY, Strause L, Deroisy R, Lecart MP, Saltman P, Franchimont P (1989) Preliminary report of decreased serum magnesium in postmenopausal osteoporosis. Magnesium 8(2):106–109PubMedGoogle Scholar
  3. 3.
    Steidl L, Ditmar R (1991) Blood magnesium, calcium and zinc in osteoporosis. Acta Univ Palacki Olomuc Fac Med 129:91–98PubMedGoogle Scholar
  4. 4.
    Ditmar R, Steidl L (1989) The significance of magnesium in orthopedics. Magnesium in osteoporosis. Acta Chir Orthop Traumatol Cech 56(2):143–159PubMedGoogle Scholar
  5. 5.
    Cohen L (1988) Recent data on magnesium and osteoporosis. Magnes Res 1–2:85–87Google Scholar
  6. 6.
    Wallach S (1990) Effects of magnesium on skeletal metabolism. Magnes Trace Elem 9(1):1–14PubMedGoogle Scholar
  7. 7.
    Yano K, Heilbrun LK, Wasnich RD, Hankin JH, Vogel JM (1985) The relationship between diet and bone mineral content of multiple skeletal sites in elderly Japanese–American men and women living in Hawaii. Am J Clin Nutr 42:877–888PubMedGoogle Scholar
  8. 8.
    Schaafsma A, Pakan I (1999) Short-term effects of a chicken egg shell powder enriched dairy-based product on bone mineral density in persons with osteoporosis or osteopenia. Bratisl Lek Listy 12:651–656Google Scholar
  9. 9.
    Sojka JE, Weaver JM (1995) Magnesium supplementation and osteoporosis. Nutr Rev 53(3):71–74PubMedGoogle Scholar
  10. 10.
    Eisinger J, Clairet D (1993) Effects of silicone, fluoride, etidronate and magnesium on bone mineral density: a retrospective study. Magnes Res 3:247–249Google Scholar
  11. 11.
    Dimai HP, Porta S, Wirnsberger G, Lindschinger M, Pamperl I, Dobnig H, Wilders-Truschnig M, Lau KH (1998) Daily oral magnesium supplementation suppresses bone turnover in young adult males. J Clin Endocrinol Metab 83(8):2742–2748CrossRefPubMedGoogle Scholar
  12. 12.
    Doyle L, Flynn A, Cashman K (1999) The effect of magnesium supplementation on biochemical markers of bone metabolism or blood pressure in healthy young adult females. Eur J Clin Nutr 53(4):255–261CrossRefPubMedGoogle Scholar
  13. 13.
    Toba Y, Kajita Y, Masuyama R, Takada Y, Suzuki K, Aoe S (2000) Dietary magnesium supplementation affects bone metabolism and dynamic strength of bone in ovariectomized rats. J Nutr 130(2):216–220PubMedGoogle Scholar
  14. 14.
    WHO (1994) Assessment of osteoporotic fracture risk and its role in screening for postmenopausal osteoporosis. WHO Technical Report Series, GenovaGoogle Scholar
  15. 15.
    Kress BC, Mizrahi IA (1999) Monitoring antiosteoporotic treatment of postmenopausal women using biochemical markers of bone turnover. Drugs Today (Barc) 35(3):181–185Google Scholar
  16. 16.
    Delmas PD (1993) Biochemical markers of bone turnover. J Bone Miner Res 8(suppl2):S549–555PubMedCrossRefGoogle Scholar
  17. 17.
    Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD (2000) Serum estradiol and sex hormone binding globulin and the risk of hip fracture. J Bone Miner Res 15(9):1835–1841CrossRefPubMedGoogle Scholar
  18. 18.
    Eyre DR (1997) Bone biomarkers as a tool in osteoporosis management. Spine 24(Suppl):S17–S24CrossRefGoogle Scholar
  19. 19.
    Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intra-nasally on bone mass and fracture rates in established osteoporosis: a dose-response study. Br Med J 305:556–561CrossRefGoogle Scholar
  20. 20.
    Harris ST, Gertz BJ, Genant HK, Eyre DR, Survill TT, Ventura JN, De Brock J, Ricerco E, Chesnut CH 3rd (1993) The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76(6):1399–1406CrossRefPubMedGoogle Scholar
  21. 21.
    Epstein S, Poser J, McClintock R, Johnston CC Jr, Bryce G, Hui S (1984) Differences in bone GLA protein with age and sex. Lancet 8372:307–310CrossRefGoogle Scholar
  22. 22.
    Chesnut CH 3rd, Harris ST (1993) Short term effect of alendronate on bone mass and bone remodeling in postmenopausal women. Osteopros Int 3(Suppl 3):S17–S19CrossRefGoogle Scholar
  23. 23.
    Clifford JR, Charles H, Chesnut CH 3rd, Nancy JSM (1997) The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82(6):1904–1910CrossRefGoogle Scholar
  24. 24.
    Rude RK, Gruber HE (2004) Magnesium deficiency and osteoporosis: animal and human observations. J Nutr Biochem 15:710–716CrossRefPubMedGoogle Scholar
  25. 25.
    Rude RK, Gruber HE, We LY, Frausto A, Mills BG (2003) Magnesium deficiency: effect on bone and mineral metabolism in the mouse. Calcif Tissue Int 72:32–41CrossRefPubMedGoogle Scholar
  26. 26.
    Creedon A, Flynn A, Cashman K (1999) The effect of moderately and severely restricted dietary magnesium intakes on bone composition and bone metabolism in the rat. Br J Nutr 82:63–71PubMedGoogle Scholar
  27. 27.
    Arnaud CD, Sanchez SD (1990) The role of calcium in osteoporosis. Annu Rev Nutr 10:397–414CrossRefPubMedGoogle Scholar
  28. 28.
    Rude RK, Oldham SB, Sharp CF Jr, Singer FR (1978) Parathyroid hormone secretion in magnesium deficiency. J Clin Endocrinol Metab 47:800–806CrossRefPubMedGoogle Scholar
  29. 29.
    Marie PJ, Travers R, Delvin EF (1983) Influence of magnesium supplementation on bone turnover in the normal young mouse. Calcif Tissue Int 35(6):755–761CrossRefPubMedGoogle Scholar
  30. 30.
    Carpenter TO, Mackowiak SJ, Troiano N, Gundberg CM (1992) Osteocalcin and its message: relationship to bone histology in Mg-deprived rats. Am J Physiol 26:E106–E114Google Scholar
  31. 31.
    Rude RK, Gruber HE, Norton HJ, Wei LY, Frausto A, Mills BG (2004) Bone loss induced by dietary magnesium reduction to 10% of the nutrient requirement in rats is associated with increased release of substance P and tumor necrosis factor-alpha. J Nutr 134(1):79–85PubMedGoogle Scholar
  32. 32.
    Makgoba MW, Datta HK (1992) The critical role of magnesium ions in osteoclast-matrix interaction: implications for divalent cations in the study of osteoclastic adhesion molecules and bone resorption. Eur J Clin Invest 22(10):692–696CrossRefPubMedGoogle Scholar
  33. 33.
    Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF (1992) Magnesium deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 110(2):169–173CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press Inc. 2009

Authors and Affiliations

  • Hasan Aydın
    • 1
    Email author
  • Oğuzhan Deyneli
    • 2
  • Dilek Yavuz
    • 2
  • Hülya Gözü
    • 3
  • Nilgün Mutlu
    • 4
  • Işık Kaygusuz
    • 2
  • Sema Akalın
    • 2
  1. 1.Department of Internal Medicine, Section of Endocrinology and MetabolismYeditepe University HospitalIstanbulTurkey
  2. 2.Department of Internal Medicine, Section of Endocrinology and MetabolismMarmara University Medical FacultyIstanbulTurkey
  3. 3.Department of Endocrinology and MetabolismKartal Lutfu Kirdar Education and Research HospitalIstanbulTurkey
  4. 4.Department of BiochemistryYeditepe University HospitalIstanbulTurkey

Personalised recommendations